Insmed Accrued Royalties (Current) decreased by 0.4% to $162.14M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.2%, from $162.51M to $162.14M.
An increase generally correlates with higher sales of licensed products, reflecting successful commercialization efforts.
The liability representing royalty payments that have been earned by third parties based on product sales but have not y...
Specific to companies with licensed technology or intellectual property, common in the biotech sector.
accrued_royalties_current| Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $148.02M | $150.17M | $152.02M | $153.43M | $155.03M | $156.97M | $158.38M | $160.05M | $161.07M | $162.51M | $163.53M | $163.85M | $162.87M | $162.14M |
| QoQ Change | — | — | +1.5% | +1.2% | +0.9% | +1.0% | +1.2% | +0.9% | +1.1% | +0.6% | +0.9% | +0.6% | +0.2% | -0.6% | -0.4% |
| YoY Change | — | — | — | — | — | +4.7% | +4.5% | +4.2% | +4.3% | +3.9% | +3.5% | +3.3% | +2.4% | +1.1% | -0.2% |